BidaskClub upgraded shares of Sinovac Biotech (NASDAQ:SVA) from a strong sell rating to a sell rating in a research note published on Wednesday.
Separately, ValuEngine downgraded Sinovac Biotech from a buy rating to a hold rating in a research note on Tuesday, June 26th.
SVA opened at $7.55 on Wednesday. Sinovac Biotech has a 52 week low of $6.06 and a 52 week high of $8.75.
About Sinovac Biotech
Sinovac Biotech Ltd., a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of vaccines against human infectious diseases in the People's Republic of China. The company's product portfolio includes vaccines against hepatitis A and B, enterovirus 71 (EV71), seasonal influenza, H5N1 and H1N1 pandemic influenza, and mumps, as well as hand, foot, and mouth diseases.
Further Reading: Understanding Market Liquidity
Receive News & Ratings for Sinovac Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sinovac Biotech and related companies with MarketBeat.com's FREE daily email newsletter.